Literature DB >> 23764374

Expression of IL-33 in the epidermis: The mechanism of induction by IL-17.

Jitlada Meephansan1, Mayumi Komine, Hidetoshi Tsuda, Masaru Karakawa, Shin-ichi Tominaga, Mamitaro Ohtsuki.   

Abstract

BACKGROUND: Interleukin (IL)-33 is a dual functional, IL-1 family member cytokine, whose exact roles in inflammatory skin diseases are still unknown. IL-17A is a key cytokine in the pathogenesis of psoriasis.
OBJECTIVES: We investigated if IL-17A could induce IL-33 in epidermal keratinocytes, and the signaling mechanisms involved.
METHODS: IL-33 levels were evaluated by RT-PCR and western blot in human keratinocytes following IL-17A simulation. IL-33 immunohistochemical staining of psoriatic skin samples was also performed and compared with that of control tissues. The role of signaling pathways downstream of IL-17A was investigated using small molecule inhibitors of EGFR, ERK, p38, and JAK. Adenovirus vector expressing dominant negative STAT1 was also utilized.
RESULTS: IL-33 and its receptor, ST2L, were expressed in the psoriatic epidermis, and the associated infiltrating cells. IL-17A induced IL-33 expression at mRNA and protein levels in a time- and concentration-dependent manner. IL-17A caused phosphorylation of EGFR, ERK, p38, and STAT1. IL-17A-induced IL-33 expression was blocked by the addition of EGFR, ERK, p38, and JAK inhibitors, and dominant negative STAT1-expressing adenovirus vector.
CONCLUSION: IL-17A induced IL-33 in NHEKs through EGFR, ERK, p38, and JAK/STAT1 pathways, which were necessary for the induction of IL-33. IL-33, induced by IL-17A in epidermal keratinocytes, may be involved in the pathophysiology of inflammatory skin diseases, including psoriasis.
Copyright © 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  IL-17; IL-33; Normal human keratinocytes; Psoriasis; Signaling pathway

Mesh:

Substances:

Year:  2013        PMID: 23764374     DOI: 10.1016/j.jdermsci.2013.04.014

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  22 in total

1.  Serum IL-33 level and IL-33 gene polymorphisms in Behçet's disease.

Authors:  Suleyman Serdar Koca; Murat Kara; Firat Deniz; Metin Ozgen; Caner Feyzi Demir; Nevin Ilhan; Ahmet Isik
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

2.  A GRHL3-regulated repair pathway suppresses immune-mediated epidermal hyperplasia.

Authors:  William M Gordon; Michael D Zeller; Rachel H Klein; William R Swindell; Hsiang Ho; Francisco Espetia; Johann E Gudjonsson; Pierre F Baldi; Bogi Andersen
Journal:  J Clin Invest       Date:  2014-10-27       Impact factor: 14.808

Review 3.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

4.  Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques.

Authors:  Dimitra P Vageli; Aikaterini Exarchou; Efterpi Zafiriou; Panagiotis G Doukas; Sotirios Doukas; Angeliki Roussaki-Schulze
Journal:  Exp Ther Med       Date:  2015-08-18       Impact factor: 2.447

5.  SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors.

Authors:  Alexandra Taracanova; Mihail Alevizos; Anna Karagkouni; Zuiy Weng; Errol Norwitz; Pio Conti; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

6.  Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response.

Authors:  Zeyu Chen; Yifan Hu; Yu Gong; Xilin Zhang; Lian Cui; Rongfen Chen; Yingyuan Yu; Qian Yu; Youdong Chen; Hongyue Diao; Jia Chen; Yuanyuan Wang; Yuling Shi
Journal:  Immunology       Date:  2020-05-25       Impact factor: 7.397

7.  Adipose-mesenchymal stromal cells suppress experimental Sjögren syndrome by IL-33-driven expansion of ST2+ regulatory T cells.

Authors:  Ousheng Liu; Junji Xu; Fu Wang; Wenwen Jin; Peter Zanvit; Dandan Wang; Nathan Goldberg; Alexander Cain; Nancy Guo; Yichen Han; Andrew Bynum; Guowu Ma; Songlin Wang; Zhangui Tang; Wanjun Chen
Journal:  iScience       Date:  2021-04-16

8.  Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal.

Authors:  Prahlad Parajuli; Rohit Anand; Chandramouli Mandalaparty; Raviteja Suryadevara; Preethi U Sriranga; Sharon K Michelhaugh; Simona Cazacu; Susan Finniss; Archana Thakur; Lawrence G Lum; Dana Schalk; Chaya Brodie; Sandeep Mittal
Journal:  Oncotarget       Date:  2016-02-02

9.  Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria.

Authors:  Wei Lin; Qiongyan Zhou; Chunbo Liu; Mengxia Ying; Suling Xu
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

10.  IL-33 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure.

Authors:  Koji Iijima; Takao Kobayashi; Kenichiro Hara; Gail M Kephart; Steven F Ziegler; Andrew N McKenzie; Hirohito Kita
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.